Abstract
Introduction: Persistent infection with high-risk human papillomavirus (HPV) types is associated with high-grade intraepithelial lesions (HSILs) and invasive cervical cancer. The host immune response plays a key role in whether HPV clears or persists. Most studies on local immune response to HPV collect cervical mucus in order to quantify secreted cytokines; however, cells located inside the tissue can release different cytokines associated with HPV infection. Objective: This study compared the cytokine levels in cervical biopsy specimens of women with abnormal colposcopic findings according to the histopathological results: low-grade intraepithelial lesion (LSIL), HSIL, and no intraepithelial lesion (NSIL). Methods: A cross-sectional study enrolling 141 cervical biopsy specimens examined the cytokine profile for interleukin (IL-) 2, IL-4, IL-10, IL-12, IL-17, and IL-23 and interferon-γ, using the Luminex assay/ELISA. Differences in cytokine levels among the cervical lesion groups were assessed using the Kruskal-Wallis test. Results: The 141 specimens included 90 HSILs, 22 LSILs, and 29 NSILs. IL-2 levels were significantly higher in NSIL samples than in LSIL or in HSIL samples (p = 0.0001) and IL-23 levels were significantly higher in NSIL than in HSIL samples (p = 0.003). Conclusions: Our study shows that in samples from the lesion site point, 2 important pro-inflammatory cytokines, IL-2 and IL-23, are downregulated in HPV lesions.
References
1.
Moscicki
AB
, Schiffman
M
, Kjaer
S
, Villa
LL
. Chapter 5: updating the natural history of HPV and anogenital cancer
. Vaccine
. 2006
;24
(Suppl 3
):S3
–51
. 2.
zur Hausen
H
. Papillomaviruses in the causation of human cancers: a brief historical account
. Virology
. 2009 Feb
;384
(2
):260
–5
. 3.
Stanley
M
. Immune responses to human papillomavirus
. Vaccine
. 2006
;24
(Suppl 1
):S16
–22
. 4.
Spracklen
CN
, Harland
KK
, Stegmann
BJ
, Saftlas
AF
. Cervical surgery for cervical intraepithelial neoplasia and prolonged time to conception of a live birth: a case-control study
. BJOG
. 2013 Jul
;120
(8
):960
–5
. 5.
Crane
JMG
. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review
. Obstet Gynecol
. 2003 Nov [cited 2019 Jul 9]
;102
(5 Pt 1
):1058
–62
. 6.
Kyrgiou
M
, Koliopoulos
G
, Martin-Hirsch
P
, Arbyn
M
, Prendiville
W
, Paraskevaidis
E
. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis
. Lancet
. 2006 Feb
;367
(9509
):489
–98
. 7.
Koeneman
MM
, Kruitwagen
RF
, Nijman
HW
, Slangen
BF
, Van Gorp
T
, Kruse
AJ
. Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers
. Expert Rev Mol Diagn
. 2015 Apr
;15
(4
):527
–46
. 8.
Castle
PE
, Hildesheim
A
, Bowman
FP
, Strickler
HD
, Walker
JL
, Pustilnik
T
, et al. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels
. J Clin Immunol
. 2002
;22
(1
):23
–7
. 9.
Daniilidis
A
, Koutsos
J
, Oikonomou
Z
, Nasioutziki
M
, Hatziparadisi
K
, Tantanasis
T
. Cytokines of cervical mucosa and human papilloma virus infection of the cervix: a descriptive study
. Acta Cytol
. 2016 Mar
;60
(1
):58
–64
. 10.
Ekalaksananan
T
, Malat
P
, Pientong
C
, Kongyingyoes
B
, Chumworathayi
B
, Kleebkaow
P
. Local cervical immunity in women with low-grade squamous intraepithelial lesions and immune responses after abrasion
. Asian Pac J Cancer Prev
. 2014
;15
(10
):4197
–201
. 11.
Otani
S
, Fujii
T
, Kukimoto
I
, Yamamoto
N
, Tsukamoto
T
, Ichikawa
R
, et al. Cytokine expression profiles in cervical mucus from patients with cervical cancer and its precursor lesions
. Cytokine
. 2019 Aug
;120
:210
–9
. 12.
Iwata
T
, Fujii
T
, Morii
K
, Saito
M
, Sugiyama
J
, Nishio
H
, et al. Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia
. Int J Clin Oncol
. 2015 Feb
;20
(1
):126
–33
. 13.
Li
B
, Zhang
L
, Zhao
J
, Tan
G
, Zhang
W
, Zhang
N
, et al. The value of cytokine levels in triage and risk prediction for women with persistent high-risk human papilloma virus infection of the cervix
. Infect Agents Cancer
. 2019 Dec
;14
(1
):16
. 14.
Marks
MA
, Viscidi
RP
, Chang
K
, Silver
M
, Burke
A
, Howard
R
, et al. Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women
. Cytokine
. 2011 Dec
;56
(3
):798
–803
. 15.
Scott
ME
, Shvetsov
YB
, Thompson
PJ
, Hernandez
BY
, Zhu
X
, Wilkens
LR
, et al. Cervical cytokines and clearance of incident human papillomavirus infection: hawaii HPV cohort study
. Int J Cancer
. 2013 Sep
;133
(5
):1187
–96
. 16.
Telesheva
L
, Dolgushina
V
, Abramovskikh
O
, Zotova
M
, Mezentseva
E
, Orner
I
, et al. [Cytokine status of cervical mucus in women with transitory and persistent course of papillomavirus infection]
. Zh Mikrobiol Epidemiol Immunobiol
. 2012 [cited 2019 Jun 24]
;(4
):118
–21
.17.
Marks
MA
, Eby
Y
, Howard
R
, Gravitt
PE
. Comparison of normalization methods for measuring immune markers in cervical secretion specimens
. J Immunol Methods
. 2012 Aug
;382
(1–2
):211
–5
. 18.
Steinman
RM
, Hawiger
D
, Nussenzweig
MC
. Tolerogenic dendritic cells
. Annu Rev Immunol
. 2003
;21
:685
–711
. 19.
Stanley
MA
. Immune responses to human papilloma viruses
. Indian J Med Res
. 2009 Sep [cited 2017 Jan 8]
;130
(3
):266
–76
.20.
Bais
AG
, Beckmann
I
, Ewing
PC
, Eijkemans
MJ
, Meijer
CJ
, Snijders
PJ
, et al. Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(−) controls
. Mediators Inflamm
. 2007
;2007
:24147
. 21.
Zhu
J
, Guo
L
, Watson
CJ
, Hu-Li
J
, Paul
WE
. Stat6 is necessary and sufficient for IL-4’s role in Th2 differentiation and cell expansion
. J Immunol
. 2001
;166
(12
):7276
–81
. 22.
Ouyang
W
, Kolls
JK
, Zheng
Y
. The biological functions of T helper 17 cell effector cytokines in inflammation
. Immunity
. 2008
;28
(4
):454
–67
. 23.
Apetoh
L
, Quintana
FJ
, Pot
C
, Joller
N
, Xiao
S
, Kumar
D
, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27
. Nat Immunol
. 2010
;11
(9
):854
–61
. 24.
Zhu
J
, Paul
WE
. CD4 T cells: fates, functions, and faults
. Blood
. 2008 Sep
;112
(5
):1557
–69
. 25.
Solomon
D
, Davey
D
, Kurman
R
, Moriarty
A
, O’Connor
D
, Prey
M
, et al. The 2001 bethesda system: terminology for reporting results of cervical cytology
. JAMA
. 2002 Apr
;287
(16
):2114
–9
. 26.
de Roda Husman
AM
, Snijders
PJ
, Stel
HV
, van den Brule
AJ
, Meijer
CJ
, Walboomers
JM
. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction
. Br J Cancer
. 1995 Aug [cited 2019 May 5]
;72
(2
):412
–7
. 27.
Mant
C
, Kell
B
, Best
JM
, Cason
J
. Polymerase chain reaction protocols for the detection of DNA from mucosal human papillomavirus types -6, -11, -16, -18, -31, and -33
. J Virol Methods
. 1997 Jul [cited 2019 May 5]
;66
(2
):169
–78
. 28.
Bernard
HU
, Chan
SY
, Manos
MM
, Ong
CK
, Villa
LL
, Delius
H
, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms
. J Infect Dis
. 1994 Nov [cited 2019 May 5]
;170
(5
):1077
–85
. 29.
Paradkar
PH
, Joshi
JV
, Mertia
PN
, Agashe
SV
, Vaidya
RA
. Role of cytokines in genesis, progression and prognosis of cervical cancer
. Asian Pac J Cancer Prev
. 2014
;15
(9
):3851
–64
. 30.
Einstein
MH
, Schiller
JT
, Viscidi
RP
, Strickler
HD
, Coursaget
P
, Tan
T
, et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns
. Lancet Infect Dis
. 2009 Jun
;9
(6
):347
–56
. 31.
Peghini
BC
, Abdalla
DR
, Barcelos
AC
, Teodoro Ld das
GVL
, Murta
EF
, Michelin
MA
. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia
. Hum Immunol
. 2012 Sep
;73
(9
):920
–6
. 32.
Lin
W
, Niu
Z
, Zhang
H
, Kong
Y
, Wang
Z
, Yang
X
, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer
. Int J Clin Exp Pathol
. 2019 [cited 2020 Apr 10]
;12
(9
):3604
–12
.33.
Song
D
, Li
H
, Li
H
, Dai
J
. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer
. Oncol Lett
. 2015 Aug
;10
(2
):600
–6
. 34.
Orbegoso
C
, Murali
K
, Banerjee
S
. The current status of immunotherapy for cervical cancer
. Rep Pract Oncol Radiother
. 2018 Nov
;23
(6
):580
–8
. 35.
Tirone
NR
, Michelin
MA
, Murta
EF
. Using cytokines to treat cervical intraepithelial and invasive neoplasia
. Recent Pat Anticancer Drug Discov
. 2010 Jun [cited 2019 Sep 29]
;5
(2
):165
–9
. 36.
Sim
GC
, Radvanyi
L
. The IL-2 cytokine family in cancer immunotherapy
. Cytokine Growth Factor Rev
. 2014 Aug
;25
(4
):377
–90
. 37.
Valle-Mendiola
A
, Gutiérrez-Hoya
A
, Lagunas-Cruz
MC
, Weiss-Steider
B
, Soto-Cruz
I
. Pleiotropic effects of IL-2 on cancer: its role in cervical cancer
. Mediators Inflamm
. 2016
;2016
:2849523
. 38.
Cua
DJ
, Tato
CM
. Innate IL-17-producing cells: the sentinels of the immune system
. Nat Rev Immunol
. 2010 Jul
;10
(7
):479
–89
. 39.
Caughron
B
, Yang
Y
, Young
MRI
. Role of IL-23 signaling in the progression of premalignant oral lesions to cancer
. PLoS One
. 2018 Apr
;13
(4
):e0196034
. 40.
Iwakura
Y
, Ishigame
H
, Saijo
S
, Nakae
S
. Functional specialization of interleukin-17 family members
. Immunity
. 2011 Feb
;34
(2
):149
–62
. 41.
Miossec
P
, Kolls
JK
. Targeting IL-17 and TH17 cells in chronic inflammation
. Nat Rev Drug Discov
. 2012 Oct
;11
(10
):763
–76
. 42.
Hou
F
, Li
Z
, Ma
D
, Zhang
W
, Zhang
Y
, Zhang
T
, et al. Distribution of Th17 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer
. Clin Chim Acta
. 2012 Nov
;413
(23–24
):1848
–54
. 43.
Gosmann
C
, Mattarollo
SR
, Bridge
JA
, Frazer
IH
, Blumenthal
A
. IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia
. J Immunol
. 2014 Sep
;193
(5
):2248
–57
. 44.
Miranda
LN
, Reginaldo
FP
, Souza
DM
, Soares
CP
, Silva
TG
, Rocha
KB
, et al. Greater expression of the human leukocyte antigen-G (HLA-G) and interleukin-17 (IL-17) in cervical intraepithelial neoplasia: analytical cross-sectional study
. Sao Paulo Med J
. 2014 Oct
;133
(4
):336
–42
. 45.
Xue
J
, Wang
Y
, Chen
C
, Zhu
X
, Zhu
H
, Hu
Y
. Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection
. Cancer Med
. 2018 Feb
;7
(2
):297
–306
. 46.
Kryczek
I
, Banerjee
M
, Cheng
P
, Vatan
L
, Szeliga
W
, Wei
S
, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
. Blood
. 2009 Aug
;114
(6
):1141
–9
. 47.
Stanley
MA
, Sterling
JC
. Host responses to infection with human papillomavirus
. Curr Probl Dermatol
. 2014
;45
:58
–74
. 48.
Lazarenko
LM
, Nikitina
OE
, Nikitin
EV
, Demchenko
OM
, Kovtonyuk
GV
, Ganova
LO
, et al. Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
. EPMA J
. 2014
;5
(1
):1
. 49.
Torres-Poveda
K
, Bahena-Román
M
, Delgado-Romero
K
, Madrid-Marina
V
. A prospective cohort study to evaluate immunosuppressive cytokines as predictors of viral persistence and progression to pre-malignant lesion in the cervix in women infected with HR-HPV: study protocol
. BMC Infect Dis
. 2018 Dec
;18
(1
):582
. 50.
Sanjabi
S
, Zenewicz
LA
, Kamanaka
M
, Flavell
RA
. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity
. Curr Opin Pharmacol
. 2009 Aug
;9
(4
):447
–53
. 51.
Berti
FCB
, Pereira
APL
, Cebinelli
GCM
, Trugilo
KP
, Brajão de Oliveira
K
. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma
. Cytokine Growth Factor Rev
. 2017 Apr
;34
:1
–13
. 52.
Li
L
, Ma
Y
, Liu
S
, Zhang
J
, Xu
XY
. Interleukin 10 promotes immune response by increasing the survival of activated CD8+ T cells in human papillomavirus 16-infected cervical cancer
. Tumour Biol
. 2016 Oct
;37
(12
):16093
–101
. 53.
Syrjänen
S
, Naud
P
, Sarian
L
, Derchain
S
, Roteli-Martins
C
, Longatto-Filho
A
, et al. Immunosuppressive cytokine interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort
. Virchows Arch
. 2009 Dec
;455
(6
):505
–15
. 54.
Brower
V
. Researchers attempting to define role of cytokines in cancer risk
. J Natl Cancer Inst
. 2005 Aug
;97
(16
):1175
–7
. 55.
Farzaneh
F
, Roberts
S
, Mandal
D
, Ollier
B
, Winters
U
, Kitchener
HC
, et al. The IL-10-1082G polymorphism is associated with clearance of HPV infection
. BJOG
. 2006 Aug
;113
(8
):961
–4
. 56.
Łaniewski
P
, Cui
H
, Roe
DJ
, Barnes
D
, Goulder
A
, Monk
BJ
, et al. Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis
. Sci Rep
. 2019 Dec
;9
(1
):7333
. 57.
Koshiol
J
, Sklavos
M
, Wentzensen
N
, Kemp
T
, Schiffman
M
, Dunn
ST
, et al. Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study
. Int J Cancer
. 2014 Jan
;134
(2
):411
–25
. 58.
Amador-Molina
A
, Hernández-Valencia
JF
, Lamoyi
E
, Contreras-Paredes
A
, Lizano
M
. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response
. Viruses
. 2013 Oct
;5
(11
):2624
–42
. 59.
Plummer
M
, de Martel
C
, Vignat
J
, Ferlay
J
, Bray
F
, Franceschi
S
. Global burden of cancers attributable to infections in 2012: a synthetic analysis
. Lancet Glob Health
. 2016 Sep
;4
(9
):e609
–16
. 60.
Serrano
B
, Brotons
M
, Bosch
FX
, Bruni
L
. Epidemiology and burden of HPV-related disease
. Best Pract Res Clin Obstet Gynaecol
. 2018 Feb
;47
:14
–26
. 61.
Guan
P
, Howell-Jones
R
, Li
N
, Bruni
L
, de Sanjosé
S
, Franceschi
S
, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer
. Int J Cancer
. 2012 Nov
;131
(10
):2349
–59
. 62.
Gravitt
PE
. The known unknowns of HPV natural history
. J Clin Invest
. 2011 Dec
;121
(12
):4593
–9
. 63.
Cohen
PA
, Jhingran
A
, Oaknin
A
, Denny
L
. Cervical cancer
. Lancet
. 2019 Jan
;393
(10167
):169
–82
. 64.
Stumbar
SE
, Stevens
M
, Feld
Z
. Cervical cancer and its precursors: a preventative approach to screening, diagnosis, and management
. Prim Care
. 2019 Mar
;46
(1
):117
–34
. 65.
Berrington de González
A
, Green
J
; International Collaboration of Epidemiological Studies of Cervical Cancer
. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies
. Int J Cancer
. 2007 Feb
;120
(4
):885
–91
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
